Cantor Fitzgerald Initiates Coverage On Cabaletta Bio with Overweight Rating, Announces Price Target of $40
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Joshua Schimmer has initiated coverage on Cabaletta Bio (NASDAQ:CABA) with an Overweight rating and a price target of $40.
October 24, 2023 | 8:55 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has initiated coverage on Cabaletta Bio with an Overweight rating and a price target of $40.
The Overweight rating from Cantor Fitzgerald indicates a positive outlook for Cabaletta Bio. The price target of $40 suggests significant upside potential from the current price. This could lead to increased investor interest and potentially a higher stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100